|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PANK3 |
Gene summary for PANK3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PANK3 | Gene ID | 79646 |
| Gene name | pantothenate kinase 3 | |
| Gene Alias | PANK3 | |
| Cytomap | 5q34 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9H999 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79646 | PANK3 | LZE4T | Human | Esophagus | ESCC | 7.14e-05 | 1.82e-01 | 0.0811 |
| 79646 | PANK3 | LZE24T | Human | Esophagus | ESCC | 1.41e-08 | 1.94e-01 | 0.0596 |
| 79646 | PANK3 | P2T-E | Human | Esophagus | ESCC | 3.43e-07 | 1.01e-01 | 0.1177 |
| 79646 | PANK3 | P4T-E | Human | Esophagus | ESCC | 1.43e-09 | 1.56e-01 | 0.1323 |
| 79646 | PANK3 | P5T-E | Human | Esophagus | ESCC | 1.95e-19 | 5.51e-01 | 0.1327 |
| 79646 | PANK3 | P8T-E | Human | Esophagus | ESCC | 7.21e-06 | 7.96e-02 | 0.0889 |
| 79646 | PANK3 | P9T-E | Human | Esophagus | ESCC | 4.18e-02 | 4.57e-02 | 0.1131 |
| 79646 | PANK3 | P10T-E | Human | Esophagus | ESCC | 1.08e-14 | 2.85e-01 | 0.116 |
| 79646 | PANK3 | P11T-E | Human | Esophagus | ESCC | 9.22e-09 | 2.85e-01 | 0.1426 |
| 79646 | PANK3 | P12T-E | Human | Esophagus | ESCC | 2.22e-10 | 1.70e-01 | 0.1122 |
| 79646 | PANK3 | P15T-E | Human | Esophagus | ESCC | 1.24e-12 | 3.41e-01 | 0.1149 |
| 79646 | PANK3 | P16T-E | Human | Esophagus | ESCC | 1.37e-12 | 5.14e-02 | 0.1153 |
| 79646 | PANK3 | P17T-E | Human | Esophagus | ESCC | 8.11e-09 | 1.68e-01 | 0.1278 |
| 79646 | PANK3 | P20T-E | Human | Esophagus | ESCC | 1.69e-06 | 5.48e-02 | 0.1124 |
| 79646 | PANK3 | P21T-E | Human | Esophagus | ESCC | 7.59e-11 | 7.60e-02 | 0.1617 |
| 79646 | PANK3 | P22T-E | Human | Esophagus | ESCC | 5.17e-15 | 3.21e-01 | 0.1236 |
| 79646 | PANK3 | P23T-E | Human | Esophagus | ESCC | 2.48e-09 | 3.39e-01 | 0.108 |
| 79646 | PANK3 | P24T-E | Human | Esophagus | ESCC | 1.16e-09 | 1.13e-01 | 0.1287 |
| 79646 | PANK3 | P26T-E | Human | Esophagus | ESCC | 1.08e-16 | 1.92e-01 | 0.1276 |
| 79646 | PANK3 | P27T-E | Human | Esophagus | ESCC | 1.68e-13 | 8.28e-02 | 0.1055 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
| GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
| GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
| GO:0009259111 | Esophagus | ESCC | ribonucleotide metabolic process | 224/8552 | 385/18723 | 4.41e-07 | 6.00e-06 | 224 |
| GO:0072521111 | Esophagus | ESCC | purine-containing compound metabolic process | 238/8552 | 416/18723 | 1.20e-06 | 1.49e-05 | 238 |
| GO:0009150111 | Esophagus | ESCC | purine ribonucleotide metabolic process | 213/8552 | 368/18723 | 1.40e-06 | 1.69e-05 | 213 |
| GO:0046390110 | Esophagus | ESCC | ribose phosphate biosynthetic process | 119/8552 | 190/18723 | 1.73e-06 | 2.06e-05 | 119 |
| GO:0006163111 | Esophagus | ESCC | purine nucleotide metabolic process | 226/8552 | 396/18723 | 2.81e-06 | 3.21e-05 | 226 |
| GO:000916516 | Esophagus | ESCC | nucleotide biosynthetic process | 150/8552 | 254/18723 | 1.12e-05 | 1.06e-04 | 150 |
| GO:0009260110 | Esophagus | ESCC | ribonucleotide biosynthetic process | 112/8552 | 182/18723 | 1.12e-05 | 1.06e-04 | 112 |
| GO:190129316 | Esophagus | ESCC | nucleoside phosphate biosynthetic process | 151/8552 | 256/18723 | 1.15e-05 | 1.08e-04 | 151 |
| GO:00338664 | Esophagus | ESCC | nucleoside bisphosphate biosynthetic process | 44/8552 | 60/18723 | 1.25e-05 | 1.15e-04 | 44 |
| GO:00340304 | Esophagus | ESCC | ribonucleoside bisphosphate biosynthetic process | 44/8552 | 60/18723 | 1.25e-05 | 1.15e-04 | 44 |
| GO:00340334 | Esophagus | ESCC | purine nucleoside bisphosphate biosynthetic process | 44/8552 | 60/18723 | 1.25e-05 | 1.15e-04 | 44 |
| GO:007252217 | Esophagus | ESCC | purine-containing compound biosynthetic process | 120/8552 | 200/18723 | 3.02e-05 | 2.51e-04 | 120 |
| GO:0009152110 | Esophagus | ESCC | purine ribonucleotide biosynthetic process | 103/8552 | 169/18723 | 4.40e-05 | 3.51e-04 | 103 |
| GO:000616417 | Esophagus | ESCC | purine nucleotide biosynthetic process | 113/8552 | 191/18723 | 1.16e-04 | 8.04e-04 | 113 |
| GO:00338655 | Esophagus | ESCC | nucleoside bisphosphate metabolic process | 77/8552 | 128/18723 | 6.71e-04 | 3.55e-03 | 77 |
| GO:00338755 | Esophagus | ESCC | ribonucleoside bisphosphate metabolic process | 77/8552 | 128/18723 | 6.71e-04 | 3.55e-03 | 77 |
| GO:00340325 | Esophagus | ESCC | purine nucleoside bisphosphate metabolic process | 77/8552 | 128/18723 | 6.71e-04 | 3.55e-03 | 77 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa012405 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
| hsa0124012 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
| hsa012402 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
| hsa007702 | Liver | HCC | Pantothenate and CoA biosynthesis | 16/4020 | 21/8465 | 7.16e-03 | 1.97e-02 | 1.09e-02 | 16 |
| hsa012403 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
| hsa007703 | Liver | HCC | Pantothenate and CoA biosynthesis | 16/4020 | 21/8465 | 7.16e-03 | 1.97e-02 | 1.09e-02 | 16 |
| hsa012404 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
| hsa0124011 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PANK3 | SNV | Missense_Mutation | c.376N>T | p.Arg126Cys | p.R126C | Q9H999 | protein_coding | deleterious(0.01) | possibly_damaging(0.835) | TCGA-BI-A0VR-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| PANK3 | SNV | Missense_Mutation | rs376150396 | c.233N>A | p.Arg78Gln | p.R78Q | Q9H999 | protein_coding | tolerated(0.08) | benign(0.193) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
| PANK3 | SNV | Missense_Mutation | c.764G>A | p.Gly255Glu | p.G255E | Q9H999 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PANK3 | SNV | Missense_Mutation | c.722G>C | p.Gly241Ala | p.G241A | Q9H999 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PANK3 | SNV | Missense_Mutation | c.779N>T | p.Arg260Ile | p.R260I | Q9H999 | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| PANK3 | SNV | Missense_Mutation | c.779G>T | p.Arg260Ile | p.R260I | Q9H999 | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| PANK3 | SNV | Missense_Mutation | novel | c.647N>T | p.Gly216Val | p.G216V | Q9H999 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| PANK3 | SNV | Missense_Mutation | novel | c.251N>G | p.Phe84Cys | p.F84C | Q9H999 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PANK3 | SNV | Missense_Mutation | novel | c.76N>G | p.Ser26Ala | p.S26A | Q9H999 | protein_coding | deleterious(0.02) | benign(0) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PANK3 | SNV | Missense_Mutation | c.376C>T | p.Arg126Cys | p.R126C | Q9H999 | protein_coding | deleterious(0.01) | possibly_damaging(0.835) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |